Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Celtics Live

57

65

3rd Quarter 10:51

Genzyme encouraged by MS drug

Genzyme, a Cambridge unit of French drug maker Sanofi SA, reported the publication of encouraging results from studies of Lemtrada, its drug candidate for treating multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is being reviewed by European regulators. At some point, Genzyme plans to seek Food and Drug Administration approval.

Continue reading below

The studies published in Lancet were chaired by Alastair Compston, a professor of neurology at the UK’s University of Cambridge. A quote from Compston was included in the Genzyme press release.

Lemtrada has the potential to “become a transformative therapy amongst the various MS treatment options that are currently available,” he said.

In a statement, Genzyme chief executive David Meeker added: “Genzyme set a new standard by comparing Lemtrada exclusively to an approved treatment in all of our studies. Publication of these findings by the Lancet highlights the importance of these results to the MS community.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week